Expression of Nkx3.1 enhances 17β-estradiol anti-tumor action in PC3 human prostate cancer cells

Asian Journal of Andrology

Volumn 9, Issue 3, 2007, Pages 353-360

  Wang, Ping ^a   Liu, Ben ^a   Luo, Jin Dan ^a   Zhang, Zhi Gen ^a   Ma, Qi ^a   Chen, Zhao Dian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

17 estradiol; Androgen independent prostate cancer; Apoptosis; Estrogen; Nkx3.1; Prostate cancer cell

Indexed keywords

APOPTOSIS RELATED PROTEIN; CASPASE 3; CELL PROTEIN; COMPLEMENTARY DNA; ESTRADIOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; NKX3 1 PROTEIN, HUMAN; NKX3-1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NITROBLUE TETRAZOLIUM TEST; PLASMID; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING; ADENOCARCINOMA; ANDROGEN INSENSITIVITY SYNDROME; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANDROGEN-INSENSITIVITY SYNDROME; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ESTRADIOL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 34347234832     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2007.00278.x     Document Type: Article

References (25)

1. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257-60.
2. Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Beer TM, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005; 103: 717-23.
3. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287-95.
4. Hedlund PO, Henriksson P. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: Effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology 2000; 55: 328.
5. Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 1996; 271: 31779-82.
6. Shen MM, Abate-Shen C. Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn 2003; 228: 767-78.
7. Jiang AL, Zhang PJ, Chen WW, Liu WW, Yu CX, Zhang JY, et al. Effect of 9-cis retinoic acid on human homeobox gene Nkx3.1 expression in prostate cancer cell line LNCaP. Asian J Andol 2006; 8: 435-41.
8. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Kallioniemi OP, et al. Loss of Nkx3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60: 6111-5.
9. Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Saatcioglu F, et al. Analysis of androgen regulated homeobox gene Nkx3.1 during prostate carcinogenesis. J Urol 2004; 172: 1134-39.
10. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F. Full-length cDNA sequence and genomic organization of human NKX3A -alterative forms and regulation by both androgens and estrogens. Gene 2000; 260: 25-36.
11. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathway, in the control of cell growth and survival. Front Biosci 2002; 7: D376-89.
12. Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J 1996; 10: 587-97.
13. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Shen MM, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999; 13: 966-77.
14. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Shen MM, Abate-Shen C, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002; 62: 2999-3004.
15. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Wu H, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006; 9: 367-78.
16. Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, Emmert-Buck MR, et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporatic prostate cancer. Genes Chromosomes Cancer 2002; 33: 201-5.
17. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD. Transdermal estrogen therapy for advanced prostate cancer-forward to the past ?. J Urol 2003; 169: 1735-7.
18. Carroll PR, Altwein J, Brawley O, Cockett A, Cooperberg M, Hirao Y, et al. Management of disseminated prostate cancer. In: Denis L, Bartsch G, Khoury S, Murai M, Partin A, editors. The 3rd International Consultation on Prostate Cancer. June 21-23, 2002, Paris, France, UK: Plymbridge Distributors; 2003; 251-84.
19. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Castagnetta L, et al. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994; 54: 1190-3.
20. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996; 56: 5594-99.
21. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R, et al. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45.
22. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
23. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, et al. Multiple Bcl-2 family members demonstrare selective dimerizations with Bax. Pro Natl Acad Sci USA 1995; 92: 7834-38.
24. Debes JD, Tindall DJ. Mechanisms of Androgen-Refractory Prostate Cancer. N Engl J Med 2004; 351: 1488-90.
25. Wolf BB, Green DR. Suicidal tendencies: Apoptotic cell death by caspase family proteinases. J Biol Chem 1999; 274: 20049-52.